Aadi Bioscience, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of precision therapies targeting genetically defined cancers associated with mTOR pathway gene alterations. The company’s lead drug candidate, FYARRO, is a formulation of sirolimus bound to albumin that is currently under evaluation for its efficacy in cancers known to exhibit mTOR pathway activation. This includes tumor-agnostic indications aimed at specific genomic alterations that activate the mTOR pathway. The weighted average number of diluted shares outstanding is 27,029,942.00 reflecting potential dilution effects on existing shareholders. Furthermore, the operating expenses amount to $90,417,000.00 encompassing various operational costs incurred by the company during its research and development activities. As part of its financial obligations, the company incurred an income tax expense of $0.00 indicating its tax liabilities. The gross profit ratio is 0.88 which reflects the efficiency of the company's production and sales operations, while the income before tax ratio stands at -2.45 illustrating the firm’s pre-tax margin that indicates operational profitability prior to taxation. As of the current market analysis, the stock is affordable at $2.05 making it suitable for budget-conscious investors who are looking to participate in the potential upside of the company’s innovative therapies. The stock, however, has a low average trading volume of 200,709.00 indicating lower market activity, which may affect liquidity for some investors. With a market capitalization of $94,891,630.00 the company is classified as a small-cap player, highlighting its growth potential in a competitive industry. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, particularly in the realm of precision oncology. Moreover, it belongs to the Healthcare sector, which is driving innovation and growth as biotechnology and personalized medicine continue to advance, reflecting the ongoing evolution in cancer treatment methodologies and therapeutic options available to patients.